TapImmune (NASDAQ:MRKR) Sees Unusually-High Trading Volume

TapImmune Inc. (NASDAQ:MRKR) saw strong trading volume on Tuesday . 1,402,714 shares changed hands during mid-day trading, an increase of 329% from the previous session’s volume of 327,221 shares.The stock last traded at $6.09 and had previously closed at $5.66.

Several analysts have issued reports on the stock. Roth Capital assumed coverage on shares of TapImmune in a research note on Thursday, May 30th. They issued a “buy” rating and a $10.00 target price on the stock. WBB Securities upgraded shares of TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 target price on the stock in a research note on Friday, March 29th. Janney Montgomery Scott assumed coverage on shares of TapImmune in a research note on Friday, March 1st. They issued a “buy” rating and a $6.22 target price on the stock. Zacks Investment Research upgraded shares of TapImmune from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Thursday, May 30th. Finally, ValuEngine lowered shares of TapImmune from a “buy” rating to a “hold” rating in a report on Friday, June 7th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.25.

The firm has a market capitalization of $291.07 million, a P/E ratio of -3.83 and a beta of 0.04. The company has a current ratio of 19.73, a quick ratio of 19.73 and a debt-to-equity ratio of 0.01.

TapImmune (NASDAQ:MRKR) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.05. As a group, equities analysts anticipate that TapImmune Inc. will post -0.53 earnings per share for the current year.

An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. raised its position in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,919 shares of the company’s stock after buying an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.64% of the company’s stock.

WARNING: “TapImmune (NASDAQ:MRKR) Sees Unusually-High Trading Volume” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://sportsperspectives.com/2019/06/13/tapimmune-nasdaqmrkr-sees-unusually-high-trading-volume.html.

TapImmune Company Profile (NASDAQ:MRKR)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Recommended Story: Rule of 72

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.